Investigation of a methylated BCAT1 and IKZF1 circulating tumour DNA blood test for monitoring treatment response in patients with colorectal cancer.

J Cancer Res Clin Oncol · 2026 · PMC13442765 · PMID 42228147

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Despite being inferior to the ctDNA test in identifying responders and non-responders, a change in CEA levels may still be a good indicator of disease progression, with highly significant increases in CEA levels observed in progressors compared to other treatment response groups.

also in 132,142 other papers

a clear trendno p-value reported

There was a clear trend of greater ctDNA level reductions with improved treatment response.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.